

Pharmacy Drug Policy Checklist

POLICY NAME Inbrija (levodopa inhalation powder) POLICY # 2695P

Criteria

Coverage Criteria	
	Diagnosis of advanced Parkinson's disease
	Age 18 years of age
	Ordered by or in consultation with a neurologist (doctor of the central nervous system)
	Documentation that member is experiencing "off" episodes (return of Parkinson's symptoms) while receiving a carbidopa/levodopa regiment where: • Attempts have been made to adjust the carbidopa/levodopa's dose and/or formulation in order to manage symptoms without success • Member will continue receiving with carbidopa/levodopa in combination with Inbrija
	Member has had previous inadequate responses, intolerance, or contraindication to at least two different classes of medications for the treatment of Parkinson's disease • Monoamine oxidase type B inhibitors • Dopamine agonists • Catechol-O-methyl transferase inhibitors